XanthoGenyx (tm) Inc: creating a new immuno-oncology treatment class for Interference Cancer Vaccines(tm). Initial focus is the treatment and diagnostics for Triple-Negative Breast Cancer. Planned exit is via partnering with one or more of twenty identified big pharma oncology companies.